A025 TEZEPELUMAB EFFICACY IN SEVERE ASTHMA BY SPECIFIC ALLERGEN SENSITIVITY: RESULTS FROM THE PATHWAY STUDY

Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin. In the PATHWAY phase 2b study (NCT02054130), tezepelumab significantly reduced annualized asthma exacerbation rates (AAERs) in adults with severe, uncontrolled asthma. This post hoc analysis evaluated tezepelumab in PATHWAY participants grouped by specific allergen sensitivity.